Illumina faces significant challenges from China's "unreliable entity list" and competition from Roche's new SBX technology, impacting its growth prospects. Despite a 37% stock decline since August, ...

Illumina Inc. (Nasdaq: ILMN), a genomics and molecular diagnostics company headquartered in San Diego, closed in late January on its acquisition of Boulder-based biotech firm SomaLogic Inc.

Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 ...

On Monday, Illumina, Inc. (NASDAQ:ILMN) agreed to acquire Standard BioTools’ (NASDAQ:LAB) subsidiary, SomaLogic. Following the announcement of the acquisition, Standard BioTools’ stock experienced a ...

Illumina, Inc. ILMN recently entered into a definitive agreement with Standard BioTools LAB to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets. The ...

Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed ...

Illumina, Inc. ILMN recently announced the launch of Illumina Protein Prep, an assay designed to deliver superior performance for next-generation sequencing (NGS)-based proteomics discovery at scale.

SPT Labtech, a global leader in life sciences automation solutions, today announced its inclusion in an Illumina partnership program to develop Illumina Qualified automated library prep methods, ...

Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- ...